One-year Growth Hormone (GH) Treatment in Children with Non-endocrine Short Stature
スポンサーリンク
概要
- 論文の詳細を見る
The effect of one year of human growth hormone (hGH) treatment on height velocity, height SDS, height velocity SDS and bone age was studied in 71 children with non-endocrine short stature. At the start of hGH treatment, mean chronological age (CA) was 8.75 yr, mean bone age (BA) 6.63, mean height SDS -3.09SD, mean height velocity 4.4 cm/yr, mean height velocity SDS for CA -1.66SD and mean height velocity SDS for BA was -2.19SD. Subjects were divided into four groups: 22 cases with familial short stature (M 14, F 8). 16 cases with SFD short stature (M 11, F 5), 5 cases with both familial and SFD short stature (M 5), and 28 cases with idiopathic short stature (M 20, F 8). There was no significant difference in height SDS, height velocity, mean peak GH and mean sleep GH before treatment among these four groups. The children received rhGH at a dose of 0.5U/kg/week 6-7 times a week subcutaneously.<BR>During hGH treatment, 8 cases developed pubertal sign. Since there was no significant difference in the effect hGH treatment between prepubertal group and pubertal group, both group were analyzed together. After one-year hGH treatment, mean height SDS increased significantly to -2.63SD (+0.44SD), mean height velocity to 7M5 cm/yr (+2.63cm/yr), height velocity SDS for CA to+ L62 SD (+3.84SD) and height velocity SDS for BA to +1.63SD (+ 3.845D). There was no significant difference in these values among four groups. During hGH treatment, plasma IGF- I levels increased significantly, but serum osteocalcin levels remained at the same level. Bone age advanced 1.57 years and height age advanced 1.20 years during one-year hGH treatment. The mean ratio of δ bone age/δ height age was 1.34. The effectiveness judged by δheight velocity ≥2cm was 67.6% and that was 62.0% judged by Aheight velocity SDS≥2.5SD. There was no significant difference in these effectiveness among four groups.<BR>Short-term hGH treatment was useful in children with non-endocrine short stature. However, long-term effects remained to be clarified.
- 日本小児内分泌学会の論文
日本小児内分泌学会 | 論文
- 43 Common origin of the Q258X mutation in StAR gene responsible for congenital aderenal lipoid hyperplasia in Japanese
- Recent Change in the Annual Incidence of Childhood Type 2 Diabetes in the Tokyo Metropolitan Area
- A Case of Acute Lymphoblastic Leukemia with Prader-Willi Syndrome during Growth Hormone Therapy
- Characteristics of a Fulminant Onset Form of Idiopathic Type 1 Diabetes Mellitus in Japanese Children
- Different Skeletal Phenotypes in a Mother and Two Daughters with Short Stature Homeobox-Containing Haploinsufficiency